Artal Group & Invus Disclose Significant Stake in Gossamer Bio

TL;DR

**Big players Artal and Invus just revealed a major stake in Gossamer Bio, signaling potential confidence or future influence.**

AI Summary

Artal International S.C.A. and its affiliated entities, including Invus Public Equities, L.P., have reported their beneficial ownership in Gossamer Bio, Inc. (NASDAQ: GOSS) as of December 14, 2023. This filing indicates that these entities collectively own a significant stake in the pharmaceutical company, which could signal their confidence in Gossamer Bio's future prospects or potentially influence its strategic decisions. For investors, this matters because large institutional ownership can provide stability and a vote of confidence, but also means a large block of shares could be sold, impacting the stock price.

Why It Matters

Large institutional ownership can influence a company's direction and stock performance, as these entities often have a say in major corporate decisions.

Risk Assessment

Risk Level: medium — While institutional ownership can be a positive sign, a large block of shares held by a single group could also lead to volatility if they decide to sell.

Analyst Insight

Investors should monitor future filings from Artal International S.C.A. and Invus Public Equities, L.P. for any changes in their ownership stake, as significant increases or decreases could signal their evolving sentiment towards Gossamer Bio, Inc. and potentially impact the stock's performance.

Key Players & Entities

• Artal International S.C.A. (company) — filing entity and beneficial owner
• Invus Public Equities, L.P. (company) — reporting person and beneficial owner
• Gossamer Bio, Inc. (company) — subject company of the filing
• ARTAL GROUP S.A. (company) — group member
• ARTAL INTERNATIONAL MANAGEMENT S.A. (company) — group member
• INVUS PUBLIC EQUITIES ADVISORS, LLC (company) — group member
• MR. AMAURY WITTOUCK (person) — group member
• STICHTING ADMINISTRATIEKANTOOR WESTEND (company) — group member
• WESTEND S.A. (company) — group member
• December 14, 2023 (date) — date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $2.00 — Common Stock, with an exercise price of $2.00 per Share and expiration date of Januar
• $2.04 — Common Stock, with an exercise price of $2.04 per Share and expiration date of July 2

Filing Documents

• d723472dsc13g.htm (SC 13G) — 154KB
• d723472dex991.htm (EX-99.1) — 10KB
• 0001193125-24-006630.txt ( ) — 166KB

(a)

Item 1(a). Name of Issuer: Gossamer Bio, Inc. (the Issuer)

(b)

Item 1(b). Address of Issuers Principal Executive Offices: 3013 Science Park Road, San Diego, California 92121

(a)

Item 2(a). Name of Person Filing:

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence:

(c)

Item 2(c). Citizenship: (i) Invus Public Equities, L.P. (Invus Public Equities) 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC (Invus PE Advisors) 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Artal International S.C.A. (Artal International) Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg Citizenship: Luxembourg limited partnership (iv) Artal International Management S.A. (Artal International Management) Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg Citizenship: Luxembourg société anonyme (v) Artal Group S.A. (Artal Group) Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg Citizenship: Luxembourg société anonyme (vi) Westend S.A. (Westend) Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg Citizenship: Luxembourg société anonyme (vii) Stichting Administratiekantoor Westend (the Stichting) Claude Debussylaan, 46, 1082 MD Amsterdam, The Netherlands Citizenship: Netherlands foundation (viii) Mr. Amaury Wittouck Valley Park, 44, Rue de la Vallée, L-2661, Luxembourg Citizenship: Belgium The foregoing persons are hereinafter sometimes collectively referred to as the Reporting Persons.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.0001 per share (the Common Stock or Shares)

(e)

Item 2(e). CUSIP Number: 38341P102 10 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): This Item 3 is not applicable. Item 4. Ownership. (a) Amount beneficially owned: As of December 14, 2023, Invus Public Equities directly held 12,058,968 shares of Common Stock, call options exercisable for 207,000 shares of Common Stock, with an exercise price of $2.00 per Share and expiration date of January 17, 2025 and warrants (the Warrants) to purchase up to 842,912 shares of Common Stock, with an exercise price of $2.04 per Share and expiration date of July 24, 2028, subject to a 4.99% beneficial ownership limitation in the Warrants described below. At December 14, 2023, Invus Public Equities was prohibited from exercising such Warrants if, as a result of such exercise, Invus Public Equities, together with its affiliates and certain other persons for whom beneficial ownership would be aggregated, would beneficially own more than 4.99% of the total number of Shares then issued and outstanding immediately after giving effect to the exercise (the Beneficial Ownership Limitation), which percentage may be changed at a holders election upon 61 days notice to the Issuer. As a result, as of December 14, 2023, the Warrants were not exercisable and Reporting Persons beneficially owned an aggregate of 12,265,968 shares of Common Stock, consisting of (i) 12,058,968 shares of Common Stock and (ii) call options exercisable for 207,000 shares of Common Stock. The Reporting Persons disclaim beneficial ownership of any Shares the issuance of which would violate such Beneficial Ownership Limitation. Pursuant to a notice delivered to the Issuer by Reporting Persons on January 8, 2024, effective as of March 9, 2024, the Beneficial Ownership Limitation will be increased to 9.99% such that Invus Public Equities will be prohibited from exercising such Warrants if, as a result of such exercise, I